Part 5 of 7 What happens next

And the fight over the gate did not wait for tomorrow. It already ran one full round this year, and the round is worth watching closely because it shows exactly how the next one will work. Over the summer, the administration pushed Congress to delay the ban: the Office of Management and Budget wrote to the Speaker in June, the President had called publicly in April for Congress to update the law, and a Senate funding bill in August carried a delay. Republican appropriator Andy Harris, whose subcommittee produced the House ancestor of the ban, said on the record that the delay request came from the White House Office of Legislative Affairs and domestic policy advisers, not from Congress, and thirty-five state and territory attorneys general urged Congress to hold the line. What emerged in September was the compromise now in effect: the two-stage cliff. During that fight, the New York Times, NBC and others reported that the White House chief of staff's daughter had married the chief executive of a major cannabinoid supplier that June, and the White House denied any connection, saying the chief of staff "has never lobbied in favor of this or any other position on hemp with Capitol Hill." We assert nothing beyond what that record holds: the push happened, the reporting exists, and the denial is on the record beside it. What matters for tomorrow is the shape of the round, because the same machinery is loaded for the next one: Comer was circulating a delay bill as of late summer, and the Barr and Craig bill is waiting as the full replacement, its cosponsor list growing through August.

So follow the organizations and their disclosed money, because that is where the record is thickest and the names matter least. Three advocacy groups now carry the hemp industry's side of the fight, and their money maps are instructive. The U.S. Hemp Roundtable, the group this story began with, has reported $2,723,500 in federal lobbying from its 2017 registration through the middle of this year, almost all of it to Frost Brown Todd; its most recent tax return shows an organization with zero employees that paid 72.6 percent of its total spending to that same firm for legal, administrative and lobbying work combined. The Hemp Industry and Farmers of America, the newer association on whose board the cannabinoid supplier's chief executive sits, spent $955,000 on federal lobbying in just nine months spanning late 2025 and the first half of 2026, across five firms, half again more than the older American Healthy Alternatives Association has spent in its entire existence. That group, AHAA, holds the corrected figure of $640,000 in lifetime federal lobbying, and its latest tax return shows revenue down two-thirds, a six-figure deficit and assets of $17,140, even as it added three new federal lobbying firms in the three weeks around the Barr bill's introduction. The filing calendar explains part of that choreography: two firms terminated their Hemp Industry and Farmers of America registrations and registered for AHAA in the week before the bill dropped, with quarterly reports due that same week, so we grade the timing a lead and not a finding. Three disciplines govern everything in this paragraph, and we state them so no reader carries an inference we did not earn. The lobbying money went to law and lobbying firms, not to legislators; the campaign contributions in this network are small, a few tens of thousands of dollars across years. A shared lobbying firm is a procurement overlap, never evidence of a common purse. And no ownership, control or disclosed funding of any of these hemp groups by any tobacco, alcohol or pharmaceutical company is established anywhere in our records, and we have looked, hard, more than once. Read that sentence for exactly what it says and nothing more. Disclosure systems see registered lobbying and public filings; they do not see private cap tables, customer lists or donor ledgers, so an absence in the record marks the boundary of the record, not a verdict of innocence. The adjacencies the record does hold, the shared firms, the same-table coalitions, the money that moves where the filings end, are mapped dollar by dollar in our Follow the Money reporting, and that file stays open.

One dated fact belongs beside that boundary. Of the lobbying firm Ballard Partners, CBS News reported this week: "Among the firm's longest-standing clients is RAI Services Company, a subsidiary of tobacco giant Reynolds American. It has paid Ballard Partners millions of dollars since 2017, lobbying records show." Reynolds has been owned by British American Tobacco since that same year. CBS also reported that RAI Services gave "$5 million to MAGA Inc., the pro-Trump super PAC, on April 30, Federal Election Commission records show." Nothing in that reporting names hemp. Those dates sit on the same calendar as everything else in this story: 2017, the year the Roundtable took its name and its lobbyists registered; 2018, the year Charlotte's Web sat on its board; 2022, the year British American Tobacco began buying Charlotte's Web. We are pulling the Florida and federal registries on that firm now, and we will report what they show.

Here is what the ban actually does tomorrow, and what is waiting behind it, because the bills already filed are the map of the next round. Stage one, November 12, removes from the hemp definition the cannabinoids the plant cannot produce on its own. Stage two, December 11, reaches nearly everything else, measuring total THC including the acid form and throwing out any product above 0.4 milligrams of total THC per container, a threshold that most of today's shelf cannot meet. Nothing about the plant itself becomes illegal; what changes is which products count as hemp, and products that stop counting fall back under the Controlled Substances Act. The rescue and replacement bills sort into three families, and we have read them. The delay bills simply strike the 365 days and insert three years. The narrow fixes, led by the Hemp Planting Predictability Act, the most cosponsored hemp bill in Congress with forty names, protect grain and fiber farming and say nothing about intoxicants. And the replacement regimes would build a new federal architecture: Senators Wyden and Merkley carry a framework on one side, and the Barr and Craig bill carries the industry's, repealing the ban outright and routing hemp beverages into alcohol-style three-tier distribution, with three separate taxes, one of which appears nowhere in the sponsor's own summary, and with a provision our reading found that no other federal hemp or alcohol law contains: it would make possession or consumption by anyone under twenty-one a federal prohibited act, placing the young person, not the seller, on the wrong side of federal law. And buried in its definitions is a form-factor asymmetry worth reading twice. The bill's legal product universe expressly includes manufactured inhalables, vape-style products, at a fallback cap of fifty milligrams of THC per serving, ten times the five milligram fallback for anything taken orally; those are the amounts that apply if the Secretary sets no maximums within twelve months, until the Secretary sets others. The words flower and smokable appear nowhere in its text, and raw floral hemp material appears exactly once, as an express exclusion. A regime that welcomes the manufactured inhalable and never names the plant's own flower favors whoever owns the manufacturing and hardware channel that inhalables move through, a channel where the nicotine industry is already at home. That is a structural observation about who the form factor fits, printed in the caps and the definitions; it is not a claim about who wrote them. Whoever wins the next round, read the bills before the press releases, because the press releases have already been wrong about their own bills.

And the next round will be loud, so here is what the summer tells us to watch for, stated as expectation and not as prophecy. When the first stage lands, expect emergency campaigns to save hemp, and expect them to raise money on the deadline; the Roundtable's crisis messaging already runs on the twenty-eight billion dollar figure and a ninety-five percent loss estimate that is its own. Expect the delay push to return inside whatever must-pass vehicle moves next, because that is how every move in this story has been made, and because the chief executive at the center of the summer round wrote to his own list that the industry's position exists because it showed up, and that a further push was coming before year-end. Expect the fourth-quarter lobbying filings, due in January, to name the bills for the first time. What we cannot tell you is whether the carveouts pass; nobody can, and anyone who says otherwise is selling something, possibly a membership. What we can tell you is what passage would mean, because it is printed in the bill text: the surviving products would move through the distribution architecture the alcohol industry already owns, and the fence would have a gate with a tollbooth on it.

Part 6 of 7 Three fences

While hemp's gate closes, the other half of the plant's legal world is being fenced at the same time, and the two fences should be read together. Marijuana moved to Schedule III for state medical licensees in April, and what followed was not an opening but a registration gate. The DEA published a list of nearly 7,000 timely applicants for the new federal registrations at the end of October; by November 11 the list had shed 986 dispensary rows and one manufacturer, concentrated in a handful of states the Justice Department named, while entire states' applicant rows sat untouched. A departed row is not proof of a registration, the agency's own page says the list changes for several reasons, and DEA has published no list of who was actually registered, so we publish counts and not conclusions. What we can describe is the architecture: a dated application window, an agency expectation that by November 29 registered and timely-applicant businesses deal only with each other, and definitions that decide who is inside before any individual decision is made. A state medical market is not a commons, and we will not pretend it is; it is a set of state privileges being fenced again one level up. But the design features are the enclosure toolkit: the dated window, the closed trading set, exclusion by definition. And across both fences, the same molecule now holds three different legal statuses depending on paperwork and origin rather than effect, which is the exact failure the regulate-by-effect framework at the center of our work was built to name.

One more fence is being built, quietly, in the health system. On April 1, in the same month the President called on Congress to update the hemp law, Medicare's innovation center launched a pilot allowing five accountable care organizations to offer chronically ill patients up to $500 a year in hemp-derived CBD products as an engagement incentive. Read the fine print the way we did, from the agency's own pages: CMS says plainly that this is not a Medicare coverage change and that it will not pay for or reimburse a single product. No federal dollar attaches. The pilot and the ban are not separate stories: POLITICO reported this week that the head of Medicare lobbied senators over the summer to delay the ban, arguing it would interfere with his effort to make hemp-derived products available to seniors. What the pilot creates instead is a list of who is allowed on: products must be naturally derived, nothing inhalable, oral doses capped at three milligrams. Those rules exclude the converted-cannabinoid industry and the smoke-shop shelf in a single stroke, and they make the real prize the procurement decisions of five health organizations choosing suppliers for a federally blessed channel. Who wins those decisions is beginning to surface, mostly through the companies' own announcements. A week before the pilot launched, Cornbread Hemp of Louisville, Kentucky announced what it described as an exclusive contract to supply hemp products through Alliant Purchasing, a national group purchasing organization whose network, by the company's own account, includes ACOs designated to participate and 68,000 provider locations; the same release notes that a company co-founder had been elected the U.S. Hemp Roundtable's 2026 chairman, and names Realm of Caring as the company's preferred partner for real-world data. Charlotte's Web, the company this story has already met twice, maintains a CBD product line with a page addressed to participating ACOs. CMS has published no list of the five organizations, both companies' claims are their own, and drug-safety groups are challenging the pilot in court. But notice what the gate looks like from the inside. A Louisville company whose co-founder now chairs the coalition this story opened with holds the announced exclusive within a national purchasing network. The tobacco-held company holds a product line built for the channel. And the patient nonprofit from the origin story is back, this time as a data partner. The names at the new gate are the names from the old one.

Part 7 of 7 Who holds the keys

Elinor Ostrom spent a career showing that the institution defines the resource: the same plant is a different thing depending on which agency holds it, who needs a license to touch it, and which industry's rules it must move through. In 2014, hemp was agriculture, a research crop. In 2018, one sentence made it a commons with no fence at all, and the predictable boom followed, along with the predictable abuses. In 2026, the fence is going back up, and the only question that matters is the one nobody in Washington is asking out loud: who holds the keys this time? The answer taking shape in the record is not the farmers the 2018 law was sold on, and not the patients the origin stories were built on. The gate was built in a must-pass bill without a hearing, and it is being closed in a must-pass bill without a hearing, and at both ends the people who use these products, the people this was all supposedly for, were never in the room.

What we are saying is this. The sentence now called a loophole was a public, deliberate, six-year project with Kentucky fingerprints on every page of its paper trail, and the market it created was not an accident that happened to the law; it was the law working exactly as written. And the ban now closing that market was built the same way the loophole was, in a must-pass vehicle, without a hearing on the definition itself, while the distribution system most likely to inherit whatever survives belongs to the best-capitalized industry at the table. The loophole and the ban are not opposites. They are acts of the same play, the next act is already cast, and in every act the audience paid for the tickets and never got a speaking part.

The gate is closing on schedule, stage one tomorrow, stage two in December. Watch whose hands are on it. They have been there the whole time.